Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

ng a Cotara Phase II safety and efficacy trial in India in GBM patients at first relapse. In patients treated to date, Cotara appears to be safe and well tolerated.

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody. This monoclonal antibody is designed to bind to a type of DNA that is exposed only on dead and dying cells, and solid tumors have many dead and dying cells at their center. Cotara's targeting mechanism enables it to home in on these cells, delivering its radioactive payload directly to the center of the tumor mass and thereby destroying it "from the inside out," with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method which targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. Cotara is in a Phase I dosimetry trial in GBM patients in the U.S. and a Phase II safety and efficacy trial in GBM patients in India. For more information on the U.S. clinical trials, visit http://www.clinicaltrials.gov

Poster Number: 5B, Abstract No: 2072: S. Shen, R. Lustig, K.D. Judy, J.B. Fiveash, J. S. Shan, "Open-label, dose confirmation and dosimetry study of Interstitial I 131 I-chTNT-1/ B MAB for the t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Calif., July 23, 2014  Varian Medical Systems (NYSE: ... of $1.02 per diluted share in the third quarter ... by about $0.06 per diluted share due to an ... of Varian,s existing equity investment in Augmenix, a privately-held ... revenues totaled $748 million for the third quarter of ...
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 The Board ... ), a leading provider of clinical trial imaging solutions, ... has been named president and chief executive officer, effective ... in August 2013 and has held the positions of ... 2013. Dr. Charles E. Phelps , ...
Breaking Medicine Technology:Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4
... , HOLMDEL, N.J., Nov. 24 Sparta Systems, Inc., ... enterprise quality and compliance solutions, today announced that SSL International ... company for globally recognized brands such as Durex and Scholl, ... The company is now leveraging the TrackWise system to harmonize ...
... , MISSISSAUGA, Ontario, Nov. 24 CardioGenics Holdings Inc. (OTC ... the immunoassay segment of the IVD testing market, reports that ... phase of the commercialization of CardioGenics, proprietary silver coated paramagnetic ... Chimie that was executed earlier this year, CardioGenics supplied Merck ...
Cached Medicine Technology:SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3
(Date:7/23/2014)... -- For patients infected with both HIV and hepatitis ... viruses, a small study suggests. Researchers said doctors ... people with the two diseases. "The findings ... important role in the management of individuals with [hepatitis ... Sherman, a professor of medicine at the University of ...
(Date:7/23/2014)... Cancer is a disease of the genome resulting from ... from our parents strong or weak predispositions to developing ... new mutations in our cells throughout our lifetime. Although ... a long time, researchers were not able to measure ... now. A team of geneticists from the University of ...
(Date:7/23/2014)... MI (PRWEB) July 23, 2014 Ticket ... Madrid vs. Manchester United tickets at Michigan Stadium . ... International Champions Cup will be held at the Big House ... of Michigan Wolverines, will be home to a game between ... from La Liga. The game will be held on August ...
(Date:7/23/2014)... NJ (PRWEB) July 23, 2014 CarePoint ... the first hospital in New Jersey to receive the ... advanced robotics platform in the da Vinci series. This ... a profound step forward in innovation. The intuitive da ... across a wide spectrum of minimally invasive and complex ...
(Date:7/23/2014)... This report defines and segments the "EHV ... Middle East & Africa, and Americas) - Global Trends ... analysis and forecasts of the global revenue. The global ... $10 billion in 2014 to nearly $14 billion by ... browse 49 Market Tables and 10 Figures Spread Through ...
Breaking Medicine News(10 mins):Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:Genetics of cancer: Non-coding DNA can finally be decoded 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4
... Mass., Oct. 30 Repligen Corporation,(Nasdaq: RGEN ) ... Walter C. Herlihy, Ph.D., will host a conference call,and ... EST, to report,second quarter fiscal year 2009 financial results ... This call is being webcast by Thomson/CCBN and can ...
... Prices, According To New Data ... from Arlington Medical Resources, MALVERN, Penn., Oct. 30 ... the pharmaceutical and,diagnostic imaging industries, finds that echinocandins show growth in ... courses,in the January - June 2008 time period compared to 9 ...
... Visit Washington D.C. to Rally Residents to Eat Right, Move ... More and Milk Their ... by,the ups and downs of different fad diets -- which seem to ... success has been,slim. Two out of three Americans -- including 22% of ...
... Mid-Atlantic Region, ATLANTA, Oct. 30 AmeriCare ( ... the opening of its,latest franchises serving Howard, Montgomery, and ... states in the union, Maryland is in the,top 20 ... Marylanders is over the,age of 60. AmeriCare of Maryland ...
... MIAMI, Oct. 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) ... in partnership with physicians,today announced that its board of ... to 5% of the Company,s outstanding Common Stock., ... at the market price.,The purchases will be made at ...
... MED ) announced today that it will release third quarter ... 30, 2008 on,Thursday, November 6, 2008. The Company will hold ... Thursday, November 6, at 11:00 a.m. ET., Interested parties ... or can listen via a live Internet web cast, which ...
Cached Medicine News:Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 2Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 3Health News:Echinocandins Show Growth Among All Antifungal Classes 2Health News:Echinocandins Show Growth Among All Antifungal Classes 3Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Caregiving Company AmeriCare Adds Franchise in Maryland 2Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008 2
... drive system which eliminates many of ... out. There are no motor brushes, ... drive belts - resulting in a ... carry weights up to 400 pounds. ...
... The Quinton Q-Stress Cardiac Stress ... baseline wander and muscle artifact ... second to provide the highest ... Leads can be displayed in ...
... ECT WS 2000 is designed to monitor, ... cardiovascular provocative tests, (stress-testing). The system can organize ... and provide them for a quick review and ... ,The recorded ECG is transmitted via a small ...
... compact BioStress 2000 is a software driven, ... testing system. The BioStress 2000 program is ... viewing, permanent ECG strorage and retrieval and ... printer. BioStress 2000 allows a wide range ...
Medicine Products: